Lipid-lowering therapy with inclisiran in the real-world setting: Initial data from a national health care service

This publication has 27 references indexed in Scilit:

• First Report of Inclisiran Utilization for Hypercholesterolemia Treatment in Real-world Clinical Settings in a Middle East Population
  Clinical Therapeutics, 2024
• High interindividual variability in LDL-cholesterol reductions after inclisiran administration in a real-world multicenter setting in Germany
  Clinical Research in Cardiology, 2023
• The clinical effects of inclisiran, a first-in-class LDL-C lowering siRNA therapy, on the LDL-C levels in Chinese patients with hypercholesterolemia
  Journal of Clinical Lipidology, 2023
• Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: Final results from the European observational HEYMANS study
  Atherosclerosis, 2023
• Small interfering ribonucleic acid for cholesterol lowering – Inclisiran
  Journal of Clinical Lipidology, 2022
• Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis
  JACC, 2021
• PCSK9 inhibition in clinical practice: Treatment patterns and attainment of lipid goals in a large health maintenance organization
  Journal of Clinical Lipidology, 2021
• Management of dyslipidaemia in patients with coronary heart disease: Results from the ESC-EORP EUROASPIRE V survey in 27 countries
  Atherosclerosis, 2019
• The Evolving Future of PCSK9 Inhibitors
  JACC, 2018
• 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
  JACC, 2014